To address this clinical question, we evaluated the correlation between clinical outcome on anti‐EGFR treatment and tumor CD73 expression using a publicly available dataset of 70 cetuximab‐treated colorectal cancer patients (GSE5851). The gene discussed is NT5E; the disease is colorectal cancer.